Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancer Investigation|May 11, 2012
MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinomaRobert J Amato, Joe Stephenson, Sebastien Hotte, et al.
Journal of Cellular Signaling|July 1, 2020
Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI MalignanciesAmandeep Godara, Nauman S Siddiqui, Hilal Hachem, et al.
British Journal of Haematology|October 1, 2010
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanismDaniela Buglio, Vidya Mamidipudi, Noor M Khaskhely, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodologySally S Ingram, Pearl H Seo, Robert E Martell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assayClaire Bonfils, Ann Kalita, Marja Dubay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2007
Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumorsHoward H Bailey, Dona B Alberti, James P Thomas, et al.
Frontiers in Immunology|March 9, 2023
VISTA expression and patient selection for immune-based anticancer therapyAlexander S Martin, Michael Molloy, Andrey Ugolkov, et al.
Cancer Epidemiology|June 19, 2013
Diabetes, metformin use, and colorectal cancer survival in postmenopausal womenFurha Iram Cossor, Lucile L Adams-Campbell, Rowan T Chlebowski, et al.
Frontiers in Oncology|October 5, 2023
Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsRandolph J Noelle, J Louise Lines, Lionel D Lewis, et al.
Cancer Chemotherapy and Pharmacology|July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup studyRobert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Pageof 3